SALMONELLA

VolverVolver

Resultados 61 resultados LastUpdate Última actualización 15/10/2019 [16:28:00] pdf PDF

Solicitudes publicadas en los últimos 90 días / Applications published in the last 90 days

Página1 de 3 nextPage   por página


SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS

NºPublicación: WO2019195493A2 10/10/2019

Solicitante:

OHIO STATE INNOVATION FOUNDATION [US]
UNIV NORTH CAROLINA STATE [US]

Resumen de: WO2019195493A2

In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

traducir

ENHANCED SHIGELLA-ENTEROTOXIGENIC E. COLI MULTI-VALENT VACCINE

NºPublicación: WO2019195437A1 10/10/2019

Solicitante:

UNIV MARYLAND [US]

Resumen de: WO2019195437A1

The invention relates to a multivalent Shigella/Enterotoxigenic Escherichia coli vaccine for use in prophylaxis and treatment of diarrheal disease. The Shigella-ETEC vaccine provides increased coverage of a broader range of ETEC and Shigella isolates than prior vaccines, and includes CS14 antigens and serotypes (S. flexneri 7a, or S. flexneri 1b).

traducir

Methods of detecting Listeria from an environmental sample

NºPublicación: AU2019232908A1 10/10/2019

Solicitante:

NEOGEN CORP

US_2018179582_A1

Resumen de: AU2019232908A1

The present invention relates to the identification of microorganisms from an environmental sample, and in particular to the rapid identification of Listeria spp. or Salmonella spp. The methods and kits described herein provide a method of detecting Listeria spp. or Salmonella spp. without the need for an enrichment step.

traducir

METHOD FOR REMOVING MICROORGANISM, CELL, TINY VESICLE SECRETED BY SAID MICROORGANISM OR SAID CELL OR VIRUS FROM CARRIER-IMMOBILIZED ANTIBODY

NºPublicación: US2019310248A1 10/10/2019

Solicitante:

HORIBA LTD [JP]

JP_WO2017104626_A1

Resumen de: US2019310248A1

The present invention provides a method for removing a microorganism, a cell, a vesicle secreted by the microorganism or the cell, or a virus from an antibody immobilized on a carrier and to which the microorganism or the like has been bound as an antigen. The present invention also provides an immunological detection method of the microorganism or the like, including removing the microorganism or the like from an antibody immobilized on a carrier and to which the microorganism or the like has been bound as an antigen.

traducir

Combined Lysis Protocol for Comprehensive Cell Lysis

NºPublicación: CN110312570A 08/10/2019

Solicitante:

\u6D77\u5CB8\u7EBF\u751F\u7269\u7FA4\u6709\u9650\u8D23\u4EFB\u516C\u53F8

KR_20190100315_A

Resumen de: US2018187181A1

Disclosed are methods for lysis of cells, such as bacteria present in microbiomes, that combine three lysis steps—(1) heat, (2) detergent and (3) base—into a single step and that can be completed in a short period of time, e.g., a few minutes. The methods combine a normally incompatible detergent and base lysis, allows for simplified removal of detergent after lysis, and importantly, yields improved quantities of genomic DNA (gDNA) from difficult to lyse bacteria.

traducir

METHOD OF PROCESSING POULTRY AND OTHER MEAT TO REDUCE OR ELIMINATE SALMONELLA

NºPublicación: US2019297905A1 03/10/2019

Solicitante:

BIRKO CORP [US]

Resumen de: US2019297905A1

A method for reducing the incidence of Salmonella in harvested meat comprising treating the meat with an effective electrostatically charged antimicrobial solution comprising a blend of lactic and citric acids in proportions containing a predominance of lactic acid from 65:5 wt./wt. to 77:3 wt./wt. lactic acid to citric acid; and the pH of the solution is less than about 3.2.

traducir

Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject

NºPublicación: AU2018217441A1 03/10/2019

Solicitante:

NOWILL ALEXANDRE

WO_2018145180_PA

Resumen de: AU2018217441A1

The present invention refers to pharmaceutical products comprising immunogenic compositions for modulating the immune system, which therapeutically effective amount of a Immmological Response Shifter (IRS) comprising two or more immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or Stress Response Signals (SRS) in association with an antibiotic and one or more physiologically acceptable carriers, excipients, diluents or solvents. In other embodiments, the present invention refers to methods to treat severe bacterial infections, sepsis and modulating the immune system.

traducir

IMMUNOGENIC CONJUGATES AND USE THEREOF

NºPublicación: EP3544625A2 02/10/2019

Solicitante:

GLAXOSMITHKLINE BIOLOGICALS SA [BE]

CN_110214022_A

Resumen de: WO2018096007A2

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

traducir

CRP CAPTURE/DETECTION OF GRAM POSITIVE BACTERIA

NºPublicación: EP3546474A2 02/10/2019

Solicitante:

HARVARD COLLEGE [US]

US_2016311877_A1

Resumen de: EP3546474A2

Described herein are engineered microbe-targeting molecules, microbe-targeting articles, kits comprising the same, and uses thereof. Such microbe-targeting molecules, microbe-targeting articles, or the kits comprising the same can bind or capture of a microbe or microbial matter thereof, and can thus be used in various applications, such as diagnosis or treatment of an infection caused by microbes in a subject or any environmental surface.

traducir

nOMV-ANTIGEN CONJUGATES AND USE THEREOF

NºPublicación: EP3544637A1 02/10/2019

Solicitante:

GLAXOSMITHKLINE BIOLOGICALS SA [BE]

CN_110248681_A

Resumen de: WO2018096013A1

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-linker-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

traducir

A NOVEL LIVE ATTENUATED SHIGELLA VACCINE

NºPublicación: KR20190110645A 30/09/2019

Solicitante:

\uC5D0\uBCA8\uB9AC\uD050\uC5B4 \uBC14\uC774\uC624\uD14C\uD06C\uB180\uB85C\uC9C0\uC2A4 \uAC8C\uC5E0\uBCA0\uD558

ES_2636897_T3

Resumen de: WO2014037440A2

A live attenuated Shigella vaccine, which is based on a rough Shigella strain lacking LPS O-antigen which is non-invasive through a mutation of the invasion plasmid, specifically for use in the immunoprophylaxis of a subject to prevent infectious diseases, preferably enteral disease, and a Shigella strain, which is a S. flexneri 2a strain with a deletion of the rfb F, ipa B and/or ipa C genes, as well as a recombinant plasmid vector based on a mutated Shigella invasion plasmid comprising a nucleotide sequence encoding at least one heterologous antigen, wherein the plasmid is mutated in at least one of the ipa B and/or ipa C genes.

traducir

NOVEL VEGFR-2 TARGETING IMMUNOTHERAPY APPROACH

NºPublicación: SG11201907391SA 27/09/2019

Solicitante:

VAXIMM AG [CH]

CN_110291187_A

Resumen de: SG11201907391SA

vI - 1641 - C'CwwG_G Bee -1763 - C'CryG_G SqI - 1800 - C'CwwG G SgI - 5816 - C'CwwG_G - 5816 - C'CryGG Btgl - 445 - C . CryQG - 445 - C'CwwG _ G Sly1 - 5193 - C`CwwG G My' - 2646 - C'CwwG_G /kalif - 3156 - G'GATC_C Btgl - 3261 - C'CI7G_G Still - 3740 - C'CwwG G Xhol - 4816 - C'TCGA G cc 00 O C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIP0 I PCT omit IIl °nolo ow (10) International Publication Number WO 2018/149982 Al (51) International Patent Classification: C12N 1/36 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/EP2018/053918 (22) International Filing Date: 16 February 2018 (16.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17156718.3 17 February 2017 (17.02.2017) EP (71) Applicant: VAXIMM AG [CH/CH]; Hochbergerstrasse 60c, 4057 Basel (CH). (72) Inventor: LUBENAU, Heinz; An der Eselshaut 12, 67435 Neustadt an der Weinstrasse (DE). (74) Agent: WALLINGER RICKER SCHLOTTER TOST- MANN; Patent- and Rechtsanwalte, Partnerschaft mbB, ZweibriickenstraBe 5-7, 80331 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, G

traducir

PROBIOTIC PATHOGEN INHIBITION COMPOSITION AND METHOD

NºPublicación: US2019290708A1 26/09/2019

Solicitante:

MICROBIOS INC [US]

Resumen de: US2019290708A1

A bacterial composition and method that inhibits E. coli O157:H7 growth by as much as 93% and Salmonella growth by as much as 97%, together with commensurate inhibition rates against the Big-Six Escherichia coli strains referred to as the non-O157 STECs that include E. coli O121:H19; E. coli O45:H2; E. coli O103:H11; E. coli O145, E. coli O26:H11; and E. coli O111. The composition is constituted of various combinations of the following unique pathogen-inhibiting bacteria: (1) Lactobacillus animalis; (2) Enterococcus faecium (3) Pediococcus acidilactici.

traducir

MULTIFUNCTIONAL NANOPROBE-ENABLED CAPTURE AND EARLY DETECTION OF MICROBIAL PATHOGENS

NºPublicación: US2019293651A1 26/09/2019

Solicitante:

UNIV JOHNS HOPKINS [US]

US_2016146813_PA

Resumen de: US2019293651A1

The presently disclosed fluidic sensor system and method comprise multifunctional nanoprobe-enabled capture for early detection of chemical and/or biological pathogens in a liquid sample. This sensor system and method can be used for food and environmental monitoring.

traducir

METHOD FOR PRODUCTION OF TLR5 AGONIST

NºPublicación: JP2019163283A 26/09/2019

Solicitante:

\u30B3\u30EA\u30A2 \u30A4\u30F3\u30B9\u30C6\u30A3\u30C6\u30E5\u30FC\u30C8 \u30AA\u30D6 \u30A4\u30F3\u30C0\u30B9\u30C8\u30EA\u30A2\u30EB \u30C6\u30AF\u30CE\u30ED\u30B8\u30FC\uFF2B\uFF2F\uFF32\uFF25\uFF21 \uFF29\uFF2E\uFF33\uFF34\uFF29\uFF34\uFF35\uFF34\uFF25 \uFF2F\uFF26 \uFF29\uFF2E\uFF24\uFF35\uFF33\uFF34\uFF32\uFF29\uFF21\uFF2C \uFF34\uFF25\uFF23\uFF28\uFF2E\uFF2F\uFF2C\uFF2F\uFF27\uFF39

US_2019127434_A1

Resumen de: KR101634380B1

The present invention relates to a production method of a TLR5 agonist protein. According to the present invention, the TLR5 agonist protein can be produced through bioengineering, and can be easily separated and purified. Particularly, by effectively removing a fusion partner used for the separation and purification, the production method can minimize possibilities for inducing an immune reaction caused by the fusion partner, and degrading bonding with TLR5. In the present invention, the TLR5 agonist protein is produced by: producing a vector including a fusion gene which is obtained by bonding a gene encoding ubiquitin with a gene encoding a TLR5 agonist protein, formed by bonding polypeptides having an amino sequence described by SEQ ID NO: 4 and polypeptides having an amino sequence described by SEQ ID NO: 2, and by bonding a gene encoding a purifying tag to the gene encoding ubiquitin; transforming a host using the vector, and expressing the fusion gene to obtain a fusion protein; bonding the fusion protein to a column where the purifying tag is bonding to obtain the fusion protein; and obtaining the TLR5 agonist protein after cutting the bonding site of ubiquitin.

traducir

COLLOIDAL GOLD TEST STRIP AND KIT FOR DETECTING CLOSTRIDIUM DIFFICILE

NºPublicación: WO2019179174A1 26/09/2019

Solicitante:

HANGZHOU GRAND BIOTECH CO LTD [CN]

CN_108445212_A

Resumen de: WO2019179174A1

Provided is a colloidal gold test strip for detecting clostridium difficile comprising an absorbent pad, a base film, a gold-labeled pad and a sample pad connected in sequence, wehrein the base film is provided with a C line and a T line, wherein the C line is coated with a dCas9 antibody, and the T line is coated with a tcdB gene fragment-bovine serum albumin complex,and the gold-labeled pad contains a colloidal gold-labeled dCas9-gRNA protein nucleic acid complex. Also provided is a kit for detecting the clostridium difficile, wherein the kit comprises the colloidal gold test strip for detecting the clostridium difficile as described above.

traducir

NOVEL VACCINE ADJUVANTS BASED ON TARGETING ADJUVANTS TO ANTIBODIES DIRECTLY TO ANTIGEN-PRESENTING CELLS

NºPublicación: BR112013002940A2 24/09/2019

Solicitante:

BAYLOR RES INSTITUTE [US]

CN_103328005_A

Resumen de: US2012039916A1

Compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist; and a pharmaceutically acceptable carrier are disclosed herein. The conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation.

traducir

nOMV-ANTIGEN CONJUGATES AND USE THEREOF

NºPublicación: CN110248681A 17/09/2019

Solicitante:

\u845B\u5170\u7D20\u53F2\u5BC6\u4E1D\u514B\u83B1\u6069\u751F\u7269\u6709\u9650\u516C\u53F8

CA_3044572_A1

Resumen de: WO2018096013A1

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-linker-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

traducir

Methods for Detecting Microorganisms Using Microorganism Detection Protein and Other Applications of Cell Binding Components

NºPublicación: US2019276868A1 12/09/2019

Solicitante:

LABORATORY CORP AMERICA HOLDINGS [US]

WO_2019173838_A1

Resumen de: US2019276868A1

Disclosed herein are methods and systems for rapid detection of microorganisms using a cell binding component (CBC). The specificity of CBSs for binding microorganisms allows targeted and highly specific detection of a microorganism of interest.

traducir

METHODS FOR DETECTING MICROORGANISMS USING MICROORGANISM DETECTION PROTEIN AND OTHER APPLICATIONS OF CELL BINDING COMPONENTS

NºPublicación: WO2019173838A1 12/09/2019

Solicitante:

LABORATORY CORP AMERICA HOLDINGS [US]
ERICKSON STEPHEN [US]
GIL JOSE S [US]
NGUYEN MINH MINDY BAO [US]
ANDERSON DWIGHT L [US]
HAHN WENDY [US]
PAULSON JOHN [US]

US_2019276868_A1

Resumen de: WO2019173838A1

Disclosed herein are methods and systems for rapid detection of microorganisms using a cell binding component (CBC). The specificity of CBSs for binding microorganisms allows targeted and highly specific detection of a microorganism of interest.

traducir

USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER

NºPublicación: US2019275128A1 12/09/2019

Solicitante:

CLEVELAND BIOLABS INC [US]

US_2018344823_A1

Resumen de: US2019275128A1

The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.

traducir

Multiple antigen presenting immunogenic composition, and methods and uses thereof

NºPublicación: KR20190104631A 10/09/2019

Solicitante:

\uCE60\uB4DC\uB7F0'\uC988 \uBA54\uB514\uCEEC \uC13C\uD130 \uCF54\uD3EC\uB808\uC774\uC158

JP_2019104758_A

Resumen de: AU2012253359A1

The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time.

traducir

肠炎沙门菌glpK基因缺失的应用

NºPublicación: CN110205277A 06/09/2019

Solicitante:

\u6CB3\u5317\u79D1\u6280\u5E08\u8303\u5B66\u9662

Resumen de: CN110205277A

本发明公开了一种肠炎沙门菌glpK基因缺失的应用,利用λ‑Red重组技术构建肠炎沙门菌glpK基因缺失株,并对其生物学特性和毒力进行研究,明确了glpK基因缺失引起肠炎沙门菌毒力下降,为设计肠炎沙门菌疫苗靶点提供参考,进而防治肠炎沙门菌感染。

traducir

IMMUNOGENIC CONJUGATES AND USE THEREOF

NºPublicación: CN110214022A 06/09/2019

Solicitante:

\u845B\u5170\u7D20\u53F2\u5BC6\u4E1D\u514B\u83B1\u6069\u751F\u7269\u6709\u9650\u516C\u53F8

CA_3044569_A1

Resumen de: WO2018096007A2

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

traducir

NOVEL IMMUNOGENIC FORMULATIONS COMPRISING LINEAR OR BRANCHED POLYACRYLIC ACID POLYMER ADJUVANTS

Nº publicación: JP2019524873A 05/09/2019

Solicitante:

\u30E1\u30EA\u30A2\u30EB \u30A4\u30F3\u30B3\u30FC\u30DD\u30EC\u30A4\u30C6\u30C3\u30C9,
\u30B5\u30CE\u30D5\u30A3 \u30D1\u30B9\u30C4\u30FC\u30EB

MX_2018015787_A

Resumen de: WO2017218819A1

The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.

traducir

Página1 de 3 nextPage por página

punteroimgVolver